Table 2 Outcomes by therapy in predominantly classic CNV.

Therapy	Trial	No of treated eyes	No of placebo eyes	Proportion of eyes with <3 lines of visual acuity loss
PDT‐V	TAP Investigation10	159	83	At 1 year: 67% treated v 40% placebo (p<0.001)
				At 2 years: 59% treated v 31% placebo (p<0.001)
Pegaptanib sodium	EOP1003 and 1004*	74	79	At 1 year: 68% treated (0.3 mg) v 57.5% placebo
Anecortave acetate (AA)	C‐98‐0317	25	26	At 1 year: 84% treated (15 mg) v 50% placebo (p = 0.01)

*These data have not been published—values estimated from data on file at the FDA: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053B1_02_FDA‐Backgrounder.pdf.